acute-myeloid-leukemia

Documents about acute-myeloid-leukemia

• Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation#1047749ClinicalTrials.gov
• Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy#916382ClinicalTrials.gov
• Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia#993529ClinicalTrials.gov
• Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Patients With Advanced Hematologic Malignancies#834802ClinicalTrials.gov
• Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome#864374ClinicalTrials.gov
• Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant#913133ClinicalTrials.gov
• Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)#877333ClinicalTrials.gov
• IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT#882355ClinicalTrials.gov
• Interferon-α Prevents Leukemia Relapse of AML Patients After Transplantation#865744ClinicalTrials.gov
• A Collaborative Palliative and Leukemia Care Model for Patients With AML and MDS Receiving Non-Intensive Therapy#908773ClinicalTrials.gov
• A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant#905059ClinicalTrials.gov
• Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients#979971ClinicalTrials.gov
• In-situ polymerization-mediated glycan density measurement on extracellular vesicle surface for acute myeloid leukemia diagnosis.#227804NCBI PubMed Central
• Specific F1 ATP synthase inhibition delivers transient mitochondrial stress for selective targeting of acute myeloid leukemia#444932bioRxiv / medRxiv
• Supplemental Materials for#467961Figshare
• Diagnostico laboratorial das leucemias mielóides agudas#612914Lume 5.8
• Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia#839290ClinicalTrials.gov
• Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation#842620ClinicalTrials.gov
• Quality of Life Model for Older Patients With AML#850864ClinicalTrials.gov
• Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML#862965ClinicalTrials.gov
• Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant#882558ClinicalTrials.gov
• Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling#907480ClinicalTrials.gov
• Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML#908075ClinicalTrials.gov
• Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML#969431ClinicalTrials.gov
• Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML Patients#1046078ClinicalTrials.gov
• PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML#426779ClinicalTrials.gov
• Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies#979376ClinicalTrials.gov
• IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.#825750ClinicalTrials.gov
• CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey#865208ClinicalTrials.gov
• The Plasmacytoid Dendritic Cell CD123+ Compartment in Acute Leukemia with or without RUNX1 Mutation: High Inter-Patient Variability Disclosed by Immunophenotypic Unsupervised Analysis and Clustering#1000714HAL (France)
• NK Cells in Cord Blood Transplantation#877345ClinicalTrials.gov
• A novel prognostic scoring system HATS for acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.#709NCBI PubMed Central
• Lovastatin Targets LIPA to Induce ER Stress-Mediated Apoptosis in Acute Myeloid Leukemia: A Multi-Omics Study.#152213NCBI PubMed Central
• Minimal residual disease is detectable in peripheral blood of patients with acute myeloid leukemia and provides prognostic information#354286IRIS
• Safety and Activity of Digoxin With Decitabine in Adult AML and MDS#846861ClinicalTrials.gov
• Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML#847672ClinicalTrials.gov
• Oral Arsenic Trioxide for NPM1-mutated AML#887991ClinicalTrials.gov
• Pre-hospital Risk Factors for Invasive Fungal Infection#917573ClinicalTrials.gov
• Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India#878449ClinicalTrials.gov
• BCX-1777 in Treating Patients With Refractory Cancer#994976ClinicalTrials.gov
• A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.#993650ClinicalTrials.gov
• LILRB4 STAR-T Cells in the Treatment of R/R AML/CMML#805504ClinicalTrials.gov
• Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies#1007931ClinicalTrials.gov
• Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit#841109ClinicalTrials.gov
• Optimal minimal residual disease threshold in pediatric acute myeloid leukemia: A retrospective cohort study based on the TARGET database.#168155NCBI PubMed Central
• NOVEL RNA-BASED CANCER VACCINE FOR AML IMMUNOTHERAPY#330631ScholarBank@NUS
• Application and challenges of chimeric antigen receptor T cell therapy in the treatment of acute myeloid leukemia (Review).#330731NCBI PubMed Central
• Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AML#405187ClinicalTrials.gov
• AI-Based Computational Model Integrating Routinely Acquired Blood Parameters for Triage and Early Detection of Acute Myeloid Leukemia.#430760NCBI PubMed Central
• Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD#800589ClinicalTrials.gov